

GLAND PHARMA LIMITED

April 28, 2023

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Scrip Code: 543245

Sub: <u>Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Thursday**, **18**th **May 2023**, *inter alia*, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2023.

Trading Window:

In continuation to our earlier intimation dated March 24, 2023; this is to inform you that the trading window, which was closed from **Saturday**, **25**th **March 2023** in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Sunday**, **21**st **May 2023**.

Earnings Call:

The Investor/Analyst call details will be intimated to the stock exchanges and published on the Company's website (www.glandpharma.com) in due course.

This is for your information and records.

Yours truly, For Gland Pharma Limited

P Sampath Kumar Company Secretary and Compliance Officer

Regd. Office:

Tel: +91-8455-699999